Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --

3Q09 Corporate Highlights:

  • Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd.
  • Made significant progress in commercial readiness activities
  • Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations
  • Appointed Bradford S. Goodwin to board as director and Audit Committee chairman

Upcoming 2009 Milestones:

  • FDA PDUFA date November 16, 2009 for Qutenza NDA to manage pain associated with PHN

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009.

During the third quarter of 2009, NeurogesX prioritized three key initiatives: 1) supporting the ongoing U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Qutenza for postherpetic neuralgia (PHN), 2) preparing for potential commercial launch of Qutenza in the United States pending FDA approval and 3) supporting Astellas Pharma Europe Ltd., the commercial partner for Qutenza in Europe, the Middle East and Africa, in their efforts to prepare for a Qutenza launch in the European Union in 2010.

In the U.S., NeurogesX is currently awaiting a decision from FDA regarding its NDA for Qutenza to manage pain associated with PHN. The agency has assigned an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009. In preparation for the possible approval and subsequent planned launch of Qutenza in the United States in the first half of 2010, the Company continued to make significant advances in a number of key product laun
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- Junto Health, a company that helps major health ... technology solutions, today announced the launch of a partnership ... health care policy consulting. Working together with SPG, Junto ... process while, at the same time, they are also ... care finance and the delivery of health care services.   ...
(Date:7/25/2015)... ... July 25, 2015 , ... Technology ... It precisely checks and adjusts the surface temperature of the measuring prism. This ... pharmaceutical industry, data traceability and documentation are key requirements. It is likely that ...
(Date:7/24/2015)... , July 24, 2015  Champions Oncology (OTC-BB: ... technology solutions and services to personalize the development and ... its financial and operational results for the fourth quarter ... Tuesday, July 28, 2015, before market open. ... the results that day at 9:00 a.m. EDT (6:00 ...
(Date:7/24/2015)... 2015 , Adds integrated small ... product offering for chronic kidney disease and oncology patients ... complications and dermatology , Increases group revenue and ... ,the Company"), a leading China -based ... biopharmaceutical products, today announced that it has acquired the ...
Breaking Biology Technology:Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 23SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4
... an information technology and Web products and services provider ... announced today that St. Luke,s Hospital & Health Network ... remote 24/7/365 IT infrastructure monitoring from CareTech,s Healthcare Infrastructure ... and monitoring of data, systems and applications located in ...
... innovative medical imaging informatics company, today announced the commercial ... Edition. Following the April release of their first commercial ... commercial version of their widely accepted DICOM ImageServer software, ... With the release of the PACS, Team Edition, ...
... windows which, thanks to a nanocoating, adjust their level ... to save energy; novel diagnostic methods and tailor-made nano-medicines ... one hand, can be used to make very efficient ... pheromones, protect vineyards from insect attack; new nanostructured materials ...
Cached Biology Technology:St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 2St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 3ClearCanvas Releases First Commercial Version of Widely Used PACS; Integrated RIS/PACS to Follow 2A world without nano? Soon hard to imagine 2A world without nano? Soon hard to imagine 3
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... 2008 American Society for Microbiology (ASM) Siemens ... presented to Adrian M. Zelazny, Staff Scientist, ... Institutes of Health (NIH). This award recognizes ... antimicrobial therapy. Dr. Zelazny is honored ...
... of supercomputers have hardware set up not just for ... seemingly random data. And now, a multi-institutional group of ... for these supercomputers. Applications include anywhere complex webs of ... grid stability to complex biological networks. The ...
... from infecting other cells and triggering their destruction by ... HIV-infected individuals but eventually peters out. To find out ... Infectious Diseases examined the cells that make the antibodies, ... that HIV gradually depletes the numbers of healthy, functional ...
Cached Biology News:Multithreaded supercomputer seeks software for data-intensive computing 2Multithreaded supercomputer seeks software for data-intensive computing 3
... cell-based assays utilize the membrane-permeant ester ... negatively charged fluorescent beta-lactamase substrates, CCF2 ... enter the cell, where cleavage by ... into their negatively charged forms, thereby ...
...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
...
Biology Products: